Search

In this study, a nanofiber surface loaded with apheresis platelet concentrate (APC) was produced for the first time to develop a bioactive wound dressing design. Nanofiber surface (n=5) consisting of polyurethane polymer outer layer, polyvinyl alcohol polymer middle layer, and polycaprolactone polymer matrix inner layer were produced via the electrospinning method. The surface morphologies of the produced nanofiber surfaces were examined by scanning electron microscopy. Quantitative analyzes of growth factors released from the APC-loaded composite nanofiber surfaces into phosphate-buffered saline at certain time intervals were performed with the ELISA. When the release amounts between bFGF, EGF, and PDGF-AA groups were compared, a significant difference was found in all periods (p<0.05). When the time-dependent release changes of each group were examined, there was no statistically significant difference in the bFGF group (p>0.05), but there was a significant difference between the EGF and PDGF-AA growth factors (p<0.05). [ABSTRACT FROM AUTHOR]

Copyright of Turkderm - Turkish Archives of Dermatology & Venereology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Treatment of psoriasis differs in special cases such as in women who wish to become pregnant, during pregnancy and lactation, in pediatric and geriatric populations, in the presence of obesity or chronic viral diseases, and during the COVID-19 pandemic. Due to their well-known teratogenic effect, neither topical nor systemic use of retinoids is recommended in any period of pregnancy and lactation. Literature data on treatment approaches in psoriasis in children is less than in adults, and safety data usually relate to short-term use. There is a multifactorial relationship between psoriasis and obesity; response to treatment is lower in obese patients with a body mass index greater than 30. It should be noted that the elderly have comorbidities and concomitant drug use, which increases the likelihood of side effects and drug interactions of psoriasis medications. In the presence of a viral disease, many agents used in the treatment of psoriasis carry the risk of exacerbating the infection due to their immunosuppressive properties. In such a case, the option that can be considered apart from topical therapies is narrow band phototherapy. It was observed during the COVID-19 pandemic that there had been no increase in the risk of infection-related mortality and morbidity solely due to biological therapy. [ABSTRACT FROM AUTHOR]

Copyright of Turkiye Klinikleri Archives of Lung is the property of Turkiye Klinikleri and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Topical corticosteroids and vitamin D analogs can be combined with other topical, systemic, and biological agents. The effect of methotrexate can be enhanced with ultraviolet B (UVB) or psoralen ultraviolet A (PUVA). When a biological agent remains insufficient, the first agent to be added to the treatment is methotrexate. The use of acitretin in combination with phototherapy (both UVB and PUVA) has a synergistic effect. A UVB therapy may be combined with topical tar and anthralin as well as with etanercept and adalimumab, which are anti-tumor necrosis factor-α therapies. [ABSTRACT FROM AUTHOR]

Assessment of the severity of psoriasis is versatile, and unfortunately, there is no single tool that can assess the severity of this disease in every aspect. As well as psoriasis area and severity index, other tools such as physician's global assessment and body surface area are also used in assessing the severity of psoriasis. The index used to assess quality of life is the dermatology life quality index. This section discusses the methods used in determining the severity of psoriasis, descriptions of treatment phases and goals, and measurement of treatment success. [ABSTRACT FROM AUTHOR]

Copyright of Turkiye Klinikleri Journal of Dermatology is the property of Turkiye Klinikleri and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Archives of Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Currently, cosmetic procedures for aesthetic purposes are increasing and cosmetic procedures like many medical applications carry a risk of complications. Thus, the patient's medical history, expectations, appropriate cosmetic approaches, possible cosmetic results and possible complications should be discussed in detail. In this article, complications of dermaroller,mesother- apy and platelet rich plasma (PRP) which have an increasing popularity and treatment approaches will be reviewed. [ABSTRACT FROM AUTHOR]

For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures. [ABSTRACT FROM AUTHOR]

Background and Design: Bullous pemphigoid (BP) is an autoimmune disease characterised by widespread itchy plaques and subepithelial blisterings and usually affects the elderly population. Due to the chronic nature of the disease, to prevent the side effects of chronic steroid treatment, adjuvant immunosuppressive (mycophenolate mofetil, azathioprine, methotrexate) and anti-inflammatory (tetracycline, nicotinamide, dapsone) agents may be used. In this study, we retrospectively evaluated the clinical and demographic characteristics and applied treatments of 46 patients with the diagnosis of BP and compared with literature data. Materials and Methods: We retrospectively evaluated the records of 46 patients who received clinical and histopathological diagnosis of BP and followed up in our clinic between 2006 and 2013. Results: Of the 46 patients, 22 were female and 24 male. The mean age of onset was 69.54 years (range: 18-105). The duration of the lesion ranged from 1 week to 10 months with a median duration of 8 weeks. The most frequent comorbid chronic disease was hypertension detected in 28 (60.8%) patients. Only four patients had a history of malignancy before the onset of the disease. Nineteen patients (42%) used more than 5 agents for comorbid diseases. Thirty-two patients (69.5%) used systemic corticosteroids alone and ten (22%) patients needed additional adjuvant therapies. Conclusion: BP is a major cause of morbidity in the elderly population receiving multiple drug treatment. To avoid the side effects of steroid therapy, especially in patients with severe disease, short-term use of additional immunosuppressive agents appears to be safe and effective. [ABSTRACT FROM AUTHOR]

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background and Design: The Turkish Society of Dermatology, Dermatoallergy Study Group planned a survey study to search sources of knowledge and practices of dermatologists in the field of dermatoallergy and establish a basis for further educational activities and projects. Materials and Methods: In this survey, a questionnaire consisting of 42 questions was completed by the participants for detailed evaluation of their practices of patch, photopatch, prick, autologous serum skin testing, drug tests and occupational dermatitis, indications, number of applications, background sources, and allergen panel used. The survey was carried on either under the supervision of the group members in their area or by distributing and collecting the questionnaire during the Dermatoallergy panel of the 21st Prof. Dr. Lütfü Tat Symposium held in Ankara on 13-17 November 2013. Results: The results of our survey revealed that the most commonly used tests in dermatoallergy practice were prick test, patch test, drug test, autologous serum skin testing, and photopatch test, respectively. Conclusion: We found out that most of the dermatologists in Turkey have the sufficient knowledge and practice to perform dermatoallergy tests. However, further scientific training courses on oral food challenge and drug provocation tests are required to improve the practice of dermatologists. [ABSTRACT FROM AUTHOR]

Amaç: Psoriasisli hastalarda PsA taraması için değişken performansa sahip çeşitli araçlar geliştirilmiştir. PsA için optimal bir tarama aracı hala karşılanmamış bir ihtiyaçtır. Bu çalışma ile ilgili farklı tutulum tiplerini tespit edebilecek Türkçe yeni bir tarama aracı geliştirmeyi amaçladık. Yöntem: On bir romatolog/on dermatologdan oluşan bir çekirdek grup belirlendi ve PubMed'de 15 Ağustos 2020'ye kadar "psoriatik artrit" anahtar kelimesi kullanılarak sistematik bir literatür taraması yapıldı. İnceleme, PEST, PASE, EARP, STRIPP, SIPAS, SIPAT, TOPAS-II, GEPARD, PASQ, CONTEST, Roman, kısa ve basit tarama anketi adlı araçları ortaya çıkardı. Bu araçların her bir parçası Delphi setine dahil edildi. Delphi'nin 3 turundan sonra, yeni bir dizi tarama sorusu geliştirildi. Bulgular: Delphi'nin ilk turu için eklem, daktilit, entezit, omurga, deri-tırnak bölgelerinin yanı sıra sabah tutukluğu, işlev, tedavi ve diğerleri ile ilgili sorular da dahil olmak üzere toplam 85 soru soruldu. İlk tura katılan on yedi uzman (çekirdek gruptan 9 dermatolog/8 romatolog) ve on beş hasta (kadın/erkek= 9/6), ortalama (SS) yaşı 39,3 (10,9), tutulum tipleri periferik (%73,4), aksiyel (%40), enteseal (%33,4) ve daktilit %14) Delfi sorularını yanıtladı. Bu ilk değerlendirme sonucunda 85 sorudan 44'ü seçilerek ikinci tura taşındı. Bu sorular romatoloji ve dermatoloji dernekleri aracılığıyla üyelere iletildi. İkinci turda toplam 85 romatoloji uzmanı ve 48 dermatoloji uzmanı soruları yanıtladı. İkinci turda soru sayısı 44'ten 22'ye düşürüldü. İlk çekirdek grup içinde ikinci tur sonunda belirlenen 22 soruyu tartışmak için bir uzlaşma toplantısı yapıldı. Her soru tek tek ele alındı, bazı sorular birleştirilerek gerekirse Türkçeye uyarlandı ve soru setine son şekli verildi. Anketin son hali 6 sorudan oluşmaktadır (Tablo). Sonuç: Türkçe olarak psoriatik hastalıkta farklı tutulum alanlarını hedefleyen yeni bir tarama aracı geliştirildi. Taramada kültürel farklılıklar önemli bir rol oynamakla birlikte, Türkçe olarak geliştirilen ilk aracın klinik uygulama ve araştırma ortamlarında yardımcı olacağına inanıyoruz. Geniş bir psoriatik hasta kohortunda geçerliliğini ve güvenilirliğini anlamak için daha fazla değerlendirme yapılacaktır. [ABSTRACT FROM AUTHOR]

Background and Design: Despite the development of effective systemic treatments and new biological agents for psoriasis nowadays, topical medications are still the mainstay of treatment. Topical calcineurin inhibitors are currently used in various skin diseases. We investigated the efficacy and safety of tacrolimus, which is an alternative in topical treatment, in comparison with the present medications in plaque psoriasis. Materials and Methods: This prospective double-blind placebo-controlled study was conducted in 24 patients with the diagnosis of plaque psoriasis who were seen in Uludağ University Hospital dermatology outpatient clinic. 0.1% tacrolimus ointment, 0.1% mometasone furoate ointment, 0.005% calcipotriol ointment and placebo in encrypted bottles were randomly applied under occlusion to 27 psoriatic plaques in test chambers, every other day, for a period of 19 days. Clinic sum scores, side effects, and epidermal thickness measured by superficial ultrasound were noted before and after treatment in all microplaques. Besides, histopathologic scoring and epidermal thickness were measured in 9 patients at the end of the study. Results: The clinic sum scores and ultrasonographic epidermal thickness at the end were both significantly lower than the beginning values in all microplaques (p<0.05). The reduction in these two values with tacrolimus were significantly higher than that with placebo (p<0.001), but no difference was observed with calcipotriol (p=0.287, p=0.813, respectively). On the other hand, the reduction in these values with mometasone was significantly higher than with tacrolimus (p<0.05). Mometasone furoate was the most effective when the three ointments were compared with placebo in terms of total histopathological score and epidermal thickness. Conclusion: Tacrolimus ointment applied under occlusion is an alternative topical medication in the treatment of plaque psoriasis. Occlusion in practice requires patient compliance. Thus, studies to find a new formulation that will increase absorption of drug from thick psoriatic plaques are needed. (Turkderm 2015; 49: 107-11) [ABSTRACT FROM AUTHOR]

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Since birth, our immune system is constantly bombarded with self-antigens and foreign pathogens. To stay healthy, complex immune strategies have evolved in our immune system to maintain self-tolerance and to defend against foreign pathogens. Effector T cells are the key players in steering the immune responses to execute immune functions. While effector T cells were initially identified to be immune promoting, recent studies unraveled negative regulatory functions of effector T cells in modulating adaptive as well as innate immunity. Owing to their critical and diverse functions in controlling immune responses, the functions and regulation of effector T cells have been a subject of intense investigation. In this review, key information about T cell immunity is summarized. [ABSTRACT FROM AUTHOR]

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Archives of the Turkish Dermatology & Venerology / Turkderm is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background and Design: Pemphigus is an autoimmune disease that results in blistering of the skin and mucous membranes. In this study, we investigated the relationship between disease activity and remission with ELISA scores and direct immunofluorescence (IF) - two methods used for the detection of antibodies against desmoglein-1 (dsg-1) and desmoglein-3 (dsg-3) that are responsible for blister formation. Material and Method: Twenty-three pemphigus vulgaris patients and two pemphigus foliaceus patients were enrolled in the study. The serum levels of anti-dsg-1 and anti-dsg-3 antibodies were measured with ELISA before therapy and at 3, 6, and 12 month of clinical remission. Concurrently, direct IF was performed on perilesional skin during active disease and on normal buttock skin/lower lip mucosa in remission. The tests were repeated if relapse has occured. Results: Anti-dsg-1 was detected in 17 (73.9%) pemphigus vulgaris patients and anti-dsg-3 in 23 (100%) pemphigus vulgaris patients. In two pemphigus foliaceus patients, anti-dsg-1 values were positive, while anti-dsg-3 values were negative. A statistically significant correlation was seen between anti-dsg-1 antibody serum levels and skin severity scores (r: 0.577; p: 0.003), as well as between anti-dsg-3 antibody serum levels and oral mucosa severity scores (r: 0.539; p: 0.008). Direct IF results in 16 patients (84.2%) who achieved complete remission were negative. In 9 patients who relapsed, elevated serum values of anti-dsg-1 and/or anti-dsg- 3 were also found. Increase in serum antibody levels was detected 1-4 months before the relapse in three of them. Conclusion: In this study, we observed that serum desmoglein antibody levels correlated with disease severity and activity. In clinical remission, serial measurements of desmoglein antibodies can provide a guide for clinical follow-up and treatment modification. [ABSTRACT FROM AUTHOR]

Background and Design: In this study, we aimed to evaluate the efficacy, safety and side effects of infliximab therapy in patients followed up in our clinic with moderate-severe psoriatic patients unresponsive to conventional therapies. Material and Method: Twenty-six psoriasis patients who were given infliximab therapy in our clinic between years 2006- 2008, were retrospectively analyzed for their demographical clinical features, changes in PASI score, duration, efficacy and adverse effects of the therapy. Results: There were 15 female and 11 male psoriasis patients; ages ranging from 18 to 70 years (45.2±12.9). 17 of them were diagnosed as generalize plaque type psoriasis, 2 as eritrodermic psoriasis, 5 as generalize pustular, two of them as palmoplantar pustular psoriasis. Thirteen have associated psoriatic arthritis. All patients received 5 mg/kg intravenous infliximab infusion at weeks 0, 2, and 6, followed by every 8 weeks. Number of infliximab therapy sections was ranging from 2 to 16 and duration of treatment from 1 month to 28 months. Improvement in PASI between pretreatment and after induction therapy was statistically significant (p<0.05). Additional systemic treatment for disease activation was applied to patients receiving infliximab monotherapy at 14.-38. weeks. We observed allergic infusion reactions in 15.4% of the patients. Conclusion: In compatible with data in literature, we found that infliximab therapy provides a rapid clinical response in patients (generalized, eritrodermic and/or pustular psoriasis) who are unresponsive to immunosupressive agents or in cases which these treatment modalities cannot be used because of side effects. [ABSTRACT FROM AUTHOR]

Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. In this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Current Pediatrics / Guncel Pediatri is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Turkish Journal of Dermatology / Turk Dermatoloji Dergisis is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)